Author: Ho-Wei Lin1, Ka-Wai Tam2,3,4,5, Yi-Chun Kuan2,3,6,7,8,9
Affiliation:
1 School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
2 Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
3 Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan.
4 Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
5 Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taiwan.
6 Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.
7 Department of Neurology, Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan.
8 Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
9 Institute of Epidemiology and Preventive Medicine, College of Public Health National, Taiwan University.
Conference/Journal: Eur J Neurol
Date published: 2023 May 9
Other:
Special Notes: doi: 10.1111/ene.15839. , Word Count: 221
Background:
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Mindfulness and meditation therapies have been demonstrated as effective alternative treatments for patients with neurological disorders. However, the effects of mindfulness and meditation therapies on PD remain unclear. This meta-analysis investigated the effects of mindfulness and meditation therapies in PD patients.
Method:
A literature search was conducted using PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing mindfulness and meditation therapies with control treatments in patients with PD.
Results:
Nine articles involving eight trials were included, with a total of 337 patients. Our meta-analysis revealed that mindfulness and meditation therapies significantly improved Unified Parkinson's Disease Rating Scale Subscale III score [mean difference (MD) = -6.31, 95% confidence interval (95% CI) = -8.57 to -4.05) and cognitive function [standard mean difference (SMD) = 0.62, 95% CI = 0.23 to 1.02]. However, no significant differences were discovered between mindfulness therapies and control in gait velocity (MD = 0.05, 95% CI = -0.23 to 0.34), Parkinson's disease Questionnaire-39 summary index (MD = 0.51, 95% CI = -1.12 to 2.14), activities of daily living (SMD = -1.65, 95% CI = -3.74 to 0.45), depression (SMD = -0.43, 95% CI = -0.97 to 0.11), anxiety (SMD = -0.80, 95% CI = -1.78 to 0.19), pain (SMD = 0.79, 95% CI = -1.06 to 2.63), or sleep disturbance (SMD = -0.67, 95% CI = -1.58 to 0.24).
Conclusion:
Mindfulness and meditation therapies may serve as complementary and alternative treatments for PD patients.
Keywords: Parkinson's disease; meditation; meta-analysis; mindfulness; randomized controlled trial.
PMID: 37158296 DOI: 10.1111/ene.15839
